Articles related to MEDICAL MEETINGS AND EVENTS

Unraveling the ALS Treatment Landscape: An Insightful Webinar Pharmacists, step into an enlightening discussion about the ALS treatment landscape on June 14th from 2:00 – 3:00 PM EST. Unearth key insights from AMCP’s Market Insights Roundtable and explore strategies to navigate patient access barriers, ultimately enriching ALS patients’ quality of life. Firstly, the webinar presents a golden opportunity for pharmacists to deepen their understanding of Amyotrophic Lateral Sclerosis (ALS), a rapidly progressing neurodegenerative disease. Our distinguished speakers will guide you through the current and evolving ALS treatment landscape, emphasizing the differences between clinical trial environments and real-life experiences. Further along, you’ll gain invaluable insights into the patient journey and the burden associated with ALS. In highlighting the current access barriers that patients face, the webinar focuses on a health plan’s concerted effort to mitigate these hurdles, providing valuable lessons for all healthcare stakeholders. Lastly, the importance of collaboration in the decision-making process to minimize access to care barriers will be underscored. With panelists like Ryan Haumschild, Director of Pharmacy at Emory Healthcare and Winship Cancer Institute, and Ryan Bitton, Senior Director of Pharmacy Services at Health Plan of Nevada, this is a conversation you won’t want to miss. Join us […]

ASCO 2023 abstracts: a glimpse into groundbreaking advancements in the oncology field. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gilead Sciences and Kite Oncology are set to present 30 abstracts. Their data underscores their leadership in hard-to-treat cancers, notably metastatic breast cancer. In addition, they highlight a growing presence in lung cancer and other tumor types. Trodelvy® (sacituzumab govitecan-hziy) emerges as a promising treatment for HR+/HER2- metastatic breast cancer (mBC) with the final overall survival (OS) results from the Phase 3 TROPiCS-02 study. Its efficacy extends to metastatic urothelial cancer (UC) and advanced endometrial cancer, reinforcing its pan-tumor potential. Moreover, Yescarta® (axicabtagene ciloleucel) offers a ray of hope for adult patients with relapsed/refractory large B-cell lymphoma (LBCL). Notably, this CAR T-cell therapy demonstrates a statistical improvement over standard care in overall survival, marking a significant medical breakthrough. Gilead’s oncology pipeline, particularly for lung cancer, is expanding. The ongoing late-stage development program evaluates Trodelvy in non-small cell lung cancer (NSCLC). Also, the updated interim analysis of ARC-7, evaluating domvanalimab in first-line NSCLC, will be presented. Presentations at ASCO 2023 will also share trial updates from ongoing studies in lung cancer, triple-negative breast cancer, UC, and other solid […]

NEW YORK CITY | THE GLASSHOUSE CHELSEASATURDAY, JUNE 24, 2023 In a comprehensive in-person setting, psychiatrists will get current, clinically relevant, and practice-based updates. This full-day conference will feature interesting presentations conducted by renowned thought leaders in schizophrenia, postpartum depression, major depressive disorder, ADHD, and addiction. Each session will include a patient perspective to ensure professionals obtain practical, real-world understanding.

In a recent study presented at the American Association for Thoracic Surgery (AATS) Annual Meeting, researchers reported that more than 75% of patients who received neoadjuvant chemotherapy combined with an immune checkpoint inhibitor (ICI) were still alive and event-free at 1 year. The treatment was also well-tolerated, with a manageable rate of side effects. The 1-year event-free survival rate was 78.3%, and the 1-year overall survival rate was 88.0%. The postoperative complication rate was 35.6%, and the rate of grade 3 or higher treatment-related adverse events was 18.1%. The most common side effects were leukopenia, neutropenia, thrombocytopenia, anemia, and hyperglycemia. Overall, the results of this study suggest that neoadjuvant chemotherapy combined with an ICI is a safe and effective treatment option for patients with resectable esophageal cancer. The treatment was associated with a high rate of pCR and R0 resection, and the side effects were generally manageable.

In an interview with OBR Oncology, Hagop Kantarjian, MD, professor and chair of the leukemia department at the University of Texas MD Anderson Cancer Center, discussed the importance for young oncologists to think critically and avoid following the crowd. He warned that “herd mentality” can lead to poor decision-making and can ultimately harm patients. Dr. Kantarjian urged young oncologists to be open to new ideas and to challenge the status quo. He also emphasized the importance of lifelong learning and staying up-to-date on the latest research. By following these principles, young oncologists can make a real difference in the lives of their patients.

Phosphodiesterase-5 inhibitors (PDE5i) have been found to reduce the risk of major adverse cardiovascular events in men with both coronary artery disease (CAD) and erectile dysfunction (ED), with tadalafil showing greater cardiac benefits compared to sildenafil, according to a study presented at the American Urological Association’s annual meeting. The retrospective study analyzed over 41,000 men with CAD and ED and found that those who took tadalafil or sildenafil had significantly lower 5-year risks of heart failure, myocardial infarction, and overall mortality compared to those who received no PDE5i treatment. Tadalafil recipients had even lower risks than sildenafil recipients across all categories. The study suggests that understanding the specific differences among PDE5i medications is crucial for addressing cardiac outcomes in patients with ED and CAD, with tadalafil potentially offering superior benefits due to differences in pharmacokinetics and longer duration of efficacy. However, further research is needed before definitive conclusions can be made regarding preferential prescription of tadalafil over other PDE5i medications.